ISPOR Publishes Insights From Its First Global HTA Roundtable

Published Apr 21, 2025

Fostering International Collaboration Among Health Technology Assessment Experts

Lawrenceville, NJ, USA—April 21, 2025—ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) published the insights from its first Global Health Technology Assessment (HTA) Roundtable in an article, “The Importance of Global Collaboration and Knowledge Exchange: A Summary Report of the Global ISPOR HTA Roundtable,” in the March/April issue of Value & Outcomes Spotlight. The Society has a long legacy of convening experts for regional HTA Roundtables across the globe. This was ISPOR’s first globally focused HTA Roundtable.

The virtual ISPOR Global HTA Roundtable convened 100 HTA professionals from 53 countries around the world in Q4 2024 to connect, share best practices, and build consensus on global HTA standards. The Roundtable participants focused on 3 key topics: (1) gene therapies and other advanced therapy medicinal products (ATMPs), (2) improving access to therapies while navigating budget constraints, and (3) digital health with a focus on artificial intelligence (AI).

The participants’ consensus was that there is a strong need for greater international collaboration, transparency, and information sharing to address the common challenges HTA bodies face. The discussions also underscored the importance of adapting HTA methodologies to assess emerging technologies/ATMPs; digital health (including AI); and access to treatments. ISPOR will be holding its next Global HTA Roundtable in 2026 in response to the experts’ strong agreement that more cross-regional collaboration and information sharing was greatly needed.

“ISPOR is committed to supporting events like the Global HTA Roundtable to foster collaboration, consensus, and the evolution of HTA methodologies,” said ISPOR CEO and Executive Director, Rob Abbott. “ISPOR’s Global HTA Roundtable ties directly to 2 objectives in the Society’s new Strategic Plan 2030, including proactively horizon scanning to establish high-leverage health policy opportunities that the Society can contribute toward. It also engages broadly with stakeholders to increase the visibility and influence of health economics and outcomes research, which is vital to HTA.”

Additional information can be found at:
Global HTA Roundtable Report | HTA Strategic Initiative | HEOR by Topic: HTA | Top 10 HEOR Trends Report

###

 

ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research
(HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website
 | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  

Explore Related HEOR by Topic


Related Stories

ISPOR Europe 2026 Plenaries Announced

Sep 30, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced details for its ISPOR Europe 2026 conference. The conference is the leading global event in Europe for health economics and outcomes research (HEOR) and is scheduled for 8-11 November in Vienna, Austria with the theme, “Shaping the Future of Access Through Science and Policy.”

ISPOR and ISPE Publish Joint Real-World Evidence Transparency Position Statement

Sep 29, 2026

Transparency in research enables the public and decision makers to trust the science that underpins real-world evidence (RWE). ISPOR—The Professional Society for Health Economics and Outcomes Research and the International Society for Pharmacoepidemiology (ISPE) have published a joint RWE Transparency Position Statement.

New Study Sheds Light on QALY and Disability Debate

Sep 28, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a study showing no evidence that the use of quality-adjusted life years (QALYs) inherently disadvantages people with disabilities.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×